Table 2.

Concentrations of GW766994 in Tissues (Punch Samples) and Plasma of Cynomolgus Monkeys Treated with Intravitreal Suspension Injection, Intravitreal Implantation, or Topical Eye Drop Administration of GW766994X

GW766994X treatment condition	Tissue concentrations of GW766994 on day 29, ng/mL				Plasma concentrations of GW766994, ng/mL
Retina, dosed eye	Retina, nondosed eye	Choroid, dosed eye	Choroid, nondosed eye	Day 8	Day 15	Day 22	Day 29
Bilateral injection, 10% w/v	43,200 ± 12,100		109,000 ± 37,900			19.4 ± 7.0	11.1 ± 7.2	20.6 ± 13.5
Single-eye injection, 10% w/v	46,600 ± 29,000	69.5 ± 29.5	91,500 ± 42,900	3490 ± 92.1		6.92 ± 1.27	4.72 ± 1.54	6.99 ± 2.82
Bilateral implant, 0.1 mg	374 ± 97.2		796 ± 283		0.232 ± 0.043	0.112 ± 0.020	0.081 ± 0.017	0.071 ± 0.015
Bilateral implant, 0.3 mg	440 ± 188		1170 ± 524		0.349 ± 0.033	0.201 ± 0.028	0.164 ± 0.020	0.158 ± 0.020
Bilateral topical, 10 mg/mL	295 ± 442		3490 ± 921		3.81 ± 0.886	2.48 ± 0.882	2.45 ± 0.728	1.71 ± 0.925

Intravitreal injections were administered at 5 mg/eye per dose on days 8 and 22. The implant preloaded with approximately 0.1 mg and 0.3 mg of GW766994 were intended to release approximately 0.002 and 0.010 mg per day, respectively. Both devices were implanted on day 1. Animals dosed topically were given eye drops twice daily (0.5 mg/eye per dose), with doses approximately 8 hours apart, on days 1 to 29. n = 6 eyes analyzed for each bilateral treatment, n = 3 eyes analyzed for the single-eye treatment.